A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.

This single-arm, open-label, Phase II study assesses first-line QL1706 + bevacizumab (anti-VEGF) + platinum/etoposide chemotherapy to treat naïve ES-SCLC patients.The main questions it aims to answer are: Evaluate efficacy and safety of this quadruplet regimen in ES-SCLC Explore correlations between tumor biomarkers and treatment efficacy Participants will: Histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC). Willing to provide archived or fresh tumor tissue samples. If unavailable, enrollment may proceed per investigator assessment. At least one measurable lesion per RECIST v1.1

NCT Number	NCT07083375
Lead Sponsor	Zhijie Wang Collaborators: Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital, Tianjin Medical University Cancer Institute and Hospital, Renmin Hospital of Wuhan University, Wuhan TongJi Hospital, Peking University People's Hospital, Shanxi Province Cancer Hospital
Conditions	Extensive Small Cell Lung Cancer
Enrollment	56 participants
Start Date	2025-08-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-24